



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 8.2.2025

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai - 400070

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 8th February, 2025 - Reg.

Ref: - Disclosure under Regulation 30 & 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Saturday, 8th February, 2025 had inter-alia considered transacted and approved the following items of business:

- 1, Approved the Un-audited Financial Results along with the segment results for the quarter and nine months ended 31st December, 2024.
2. Taken on record the Limited Review Report received from the statutory auditors of the company for the quarter and nine months ended 31st December, 2024.

We wish to inform that the company has not issued any Non-Convertible Debt Securities, Non-Convertible Redeemable Preference Shares (NCRPS) and Commercial Papers or any other instruments and as such the SEBI circular no. SEBI/HO/DDHS/DDHS/CIR/P/2020/231 dated November 13, 2020 is not applicable to the company.

We herewith enclose the following:

- A. Un-Audited financial Results along with the segment results, for the quarter and nine months ended 31st December, 2024.
 - B. Limited Review Report of the Statutory Auditors for the quarter and nine months ended 31st December, 2024.
- Kindly take the above on your records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary

The meeting Commenced at 4:00 PM
The Meeting Concluded at 7:00 PM

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For The Quarter and Nine Months ended 31st December, 2024

(Rs.in lakhs)

Sl.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	48.28	120.12	109.25	248.36	297.49	374.14
2	Other income	14.68	32.63	13.98	48.91	46.12	61.86
3	Total Income (1+2)	62.96	152.75	123.23	297.27	343.61	436.00
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Impairment on Advances	-	-	-	-	75.00	75.00
	d) Fair Value Loss	60.28	-	-	-	-	-
	e) Employee benefits expense	11.12	10.33	8.45	31.53	28.12	39.37
	f) Finance costs	-	-	-	-	-	-
	g) Depreciation and amortization expense	5.81	6.27	5.66	17.39	16.46	22.51
	h) Other expenses	3.48	2.87	3.79	10.65	11.20	17.53
	Total Expenses	80.69	19.47	17.90	59.57	130.78	154.41
5	Profit/(Loss) before exceptional items and tax (3-4)	(17.73)	133.28	105.33	237.70	212.83	281.59
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	(17.73)	133.28	105.33	237.70	212.83	281.59
8	Tax expense						
	(a) Current tax	11.15	15.60	9.96	31.33	27.54	40.95
	(b) Deferred tax	(1.84)	7.29	6.87	(3.00)	19.20	43.18
	Total Tax Expense	9.31	22.89	16.83	28.33	46.74	84.13
9	Profit/(Loss) for the Period (7-8)	(27.04)	110.39	88.50	209.37	166.09	197.46
10	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit and (loss)	(69.91)	215.00	119.39	419.69	349.47	367.56
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.20
	(c) Tax on Items that will not be reclassified to profit or (loss)	(9.10)	(22.36)	(16.08)	(60.01)	(40.01)	(38.28)
	(d) Items that will be reclassified to profit and (loss)	-	-	-	-	-	-
	(e) Items that may be reclassified subsequently to profit and (loss)	-	-	-	-	-	-
	Total other Comprehensive income for the period, net of tax	(79.01)	192.64	103.31	359.68	309.46	329.48
	Total Comprehensive income (9+10)	(106.05)	303.03	191.81	569.05	475.55	526.94
11	Paid-up Equity Share Capital (Face Value Rs.10/- each)	675.31	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	-	-	2,869.84
13	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))						
	(1) Basic	(0.40)	1.63	1.31	3.10	2.46	2.92
	(2) Diluted	(0.40)	1.63	1.31	3.10	2.46	2.92

Segment wise Revenue, Results and Capital Employed for the Quarter and Nine months ended 31st December 2024

(Rs.in lakhs)

Sl.No	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	35.00	34.50	33.50	92.50	88.50	134.50
	b) Investments	27.96	118.25	89.73	204.77	255.11	301.50
	Total	62.96	152.75	123.23	297.27	343.61	436.00
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net Sales/Income from Operations	62.96	152.75	123.23	297.27	343.61	436.00
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	28.94	28.05	27.66	74.32	71.23	110.07
	b) Investments	(32.32)	118.25	89.73	204.77	255.11	301.50
	Total	(3.38)	146.30	117.39	279.09	326.34	411.57
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	14.35	13.02	12.06	41.39	113.51	129.98
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit/(loss) Before Tax	(17.73)	133.28	105.33	237.70	212.83	281.59
3	Capital Employed						
	(Segment Assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	790.79	781.47	785.90	790.79	785.90	818.54
	b) Investments	3,379.16	3,494.53	2,763.61	3,379.16	2,763.61	2,782.36
	Total	4,169.95	4,276.00	3,549.51	4,169.95	3,549.51	3,600.90

Notes :

- The above Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 08th February, 2025.
- These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- These Financial results have been subjected to limited review by the Statutory Auditors'.
- These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.slilab.com).

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 08.02.2025

(T.R.Sekhar)
Executive Director
DIN:02943146

**Independent Auditor's Review Report on the Quarter and nine months ended 31st December, 2024
Unaudited Standalone Financial Results of the Company pursuant to the Regulations 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To The Board of Directors of **SIGACHI LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **SIGACHI LABORATORIES LIMITED** ('the Company') for the quarter ended 31st December 2024 and the year to date results for the period from 01st April 2024 to 31st December 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').s
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.





Our conclusion is not modified in respect of the above matters.

For NSVR & Associates LLP

Chartered Accountants

FRN: 008801S/S200060

V Gangadhara Rao N

Partner

Membership No: 219486

UDIN: **25219486BMIRTW8517**

Place: Hyderabad

Date: 08-02-2025



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

8.2.2025

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Sigachi Laboratories Limited - Intimation of Non Applicability of Regulations
51, 52 and 54 of SEBI (LODR), Regulations, 2015 for the Quarter ended 31.12.2024 -
Reg.

With respect to above cited subject, we would like to inform your good office that the following regulations of the SEBI (LODR) Regulations, 2015, as amended, are not applicable to our company:

S No.	Particulars	Regulation	Applicability
1.	Price Sensitive Information/ disclosure of event/ Information	Reg. 51(1) & 51 (2) SEBI (LODR) Regulations, 2015	Debt
2.	Submission of Financial Results	Reg. 52(1) SEBI (LODR) Regulations, 2015	Debt
3.	Submission of line items along with Financial Results	Reg. 52(4) & 52 (6) SEBI (LODR) Regulations, 2015	Debt
4.	Asset Cover	Reg. 54(2) & 54 (3) SEBI (LODR) Regulations, 2015	Debt
5.	Utilization of issue proceeds/ material deviation in the use of proceeds	Reg. 52(7) & 52(7A) SEBI (LODR) Regulations, 2015	Debt

We hereby certify that the Company has not issued any non-convertible securities or instruments of similar nature at any time for the quarter ended 31.12.2024 and therefore the disclosures required as per aforementioned regulations are not applicable to the company.

We request you to take the above in your records.

Thanking you,

Yours Faithfully
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACC88220M1Z4 CIN : L24230TG1994PLC018786

Date: 8.2.2025

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Reg.

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the company had made its public offer (Initial Public Offer IPO) nearly about 25 years back and the Company has fully utilized the proceeds of the IPO for the purpose for which the funds were raised. The company has not raised any fresh issue after Initial public issue - through public issue, rights issue, preferential issue, QIP, etc., Hence, the Statement of deviation(s) or variation(s) is not applicable to the Company

We request you to kindly take note of this information on your record and acknowledge.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary